“One in eight women will develop breast cancer. There is a misconception that family history and having the BRCA gene are the leading causes of breast cancer. In fact, more than 85% of women who develop breast cancer have little-to-no family history of the disease. With a percentage that high, more women should be turning to genetic testing to assess their personalized cancer risk and make choices about their health that work best for them.”
I recently had the pleasure of interviewing breast cancer expert, Dr. Russell Stankiewicz, to discuss a new sporadic cancer genetic treatment called BREVAGenplus. During our interview, Dr. Stankiewicz was able to share:
- Differences between hereditary breast cancer and sporadic breast cancer
- Who is at most risk for developing breast cancer
- Who is the perfect candidate for BREVAGenplus
- What makes this test valuable to women and physicians
- Where is this testing available, the cost and insurance coverage
Click here for the complete interview.
With October being Breast Cancer awareness month, this is just one more reminder for all women to be up to date on their breast health.
Russell Stankiewicz, MD is a Clinical Assistant Professor of Obstetrics and Gynecology in The department of Obstetrics, Gynecology, and Family Medicine at The Commonwealth Medical College in Scranton, PA. He is also President and Senior partner at OB/GYN Associates of Lewisburg, P.C. Dr. Stankiewicz is board certified in Obstetrics and Gynecology, has advanced certification in Minimally Invasive Surgery, and is a certified Menopause Practitioner. He sits on multiple committees of The North American menopause Society. He is also a FAA designated Aviation Medical Examiner.
Categories: Health & Fitness